Patents Examined by Yong L Chu
  • Method for treating paroxysmal nocturnal hemoglobinuria
    Patent number: 10555923
    Abstract: The present invention provides methods for treating, controlling or mitigating paroxysmal nocturnal hemoglobinuria (PNH), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: February 11, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki Young Sohn, Jae Wha Kim
  • Method of restoring analgesic efficacy of alpha2-adrenoceptor agonists in neuropathic pain treatment
    Patent number: 10555932
    Abstract: Provided are a pharmaceutical composition including: an alpha 2 (?2)-adrenoceptor agonist; a regulator of G-protein signaling (RGS) inhibitor, an endocytosis inhibitor, or a combination thereof; and a pharmaceutically acceptable salt, and a method of relieving pain of a subject, the method including administering the pharmaceutical composition to a subject.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 11, 2020
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Key-Sun Kim, Seo-Yeon Yoon
  • Suppositories comprising cannabinoids
    Patent number: 10543190
    Abstract: This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 28, 2020
    Assignee: Axim Biotechnologies, Inc.
    Inventors: Lekhram Changoer, George Anastassov
  • Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
    Patent number: 10537537
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: January 21, 2020
    Assignees: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Transdermal drug delivery using an osmolyte and vasoactive agent
    Patent number: 10537536
    Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 21, 2020
    Assignee: BioChemics, Inc.
    Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
  • Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
    Patent number: 10537564
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: January 21, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Elfrida Benjamin
  • Isonitramine compound and composition containing same for preventing or treating metabolic diseases
    Patent number: 10537559
    Abstract: Provided are a pharmaceutical composition for preventing or treating metabolic diseases and a health food for alleviating metabolic diseases, each of which the pharmaceutical composition and the health food includes, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers, wherein such a compound exhibits effects of inhibiting fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus can be favorably utilized in the treatment of metabolic diseases, such as obesity, diabetes, and hyperlipidemia.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 21, 2020
    Assignee: INJE UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyo-Jong Lee, Yohan Park, Hyeung-Geun Park
  • Metabolic markers of attention deficit hyperactivity disorder
    Patent number: 10525020
    Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: January 7, 2020
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
  • Phenyl carbamate compound and a composition for neuroprotection comprising the same
    Patent number: 10525030
    Abstract: The present invention relates to a composition for neuroprotection comprising a phenyl carbamate compound and a method for providing neuroprotection therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases associated with neurological injury.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 7, 2020
    Assignee: BIO-PHARM SOLUTIONS CO., LTD.
    Inventor: Yong Moon Choi
  • Methods of altering programmed cell death and extending cell life
    Patent number: 10517856
    Abstract: In one aspect, a method of altering programmed cell death includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine is administered to treat a wound, hemochromatosis, traumatic brain injury, or disorders associated with chronic oxidative stress. In other aspects, isomyosmine is administered to increase blood oxygen saturation levels.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 31, 2019
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Pharmaceutical composition for treatment of HIV infection
    Patent number: 10493034
    Abstract: The invention is a pharmaceutical composition for the treatment of HIV infection; containing at least one HIV protease inhibitor as an active ingredient, as well as pharmaceutically acceptable excipients with a specific quantitative component ratio. Additionally, the invention belongs to the process of its production and to a treatment method. The inventive pharmaceutical composition has increased bioavailability and improved technological properties, such as durability, plasticity, disintegration, compared to the prototype drug.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: December 3, 2019
    Assignee: OTKRYTOE AKTSIONERNOE OBSCHESTVO “FARMASYNTEZ”
    Inventors: Vikram Singkh Puniya, Gennady Andreevich Batyunin, Natalya Yurievna Malykh
  • Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
    Patent number: 10493035
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 3, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • Oligomer-phenothiazine conjugates
    Patent number: 10485877
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 26, 2019
    Assignee: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Combination therapy for treating cancer
    Patent number: 10463671
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 5, 2019
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah K. Knutson, Kevin W. Kuntz
  • Capsazepine analogs for the treatment of cancer and other proliferative diseases
    Patent number: 10457676
    Abstract: The present disclosure relates generally to derivatives of capsazepine and methods of use thereof In some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases. In some aspects of the present disclosure, the disclosure provides capsazepine derivatives which may be useful in the treatment of cancer. Such cancers that the compounds may be used to treating include but are not limited to breast, cervical, oral, head, neck, or prostate cancer. In some aspects, the compounds may be useful in treating a tumor by direct injection of the compound into the tumor, particularly an oral tumor. In other aspects, the compounds are administered systemically. The compounds of the present disclosure may also be used to treat the pain associated with a tumor for which it is being administered.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: October 29, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cara B. Gonzales, Stanton McHardy
  • Cosmetic compositions comprising acetyl trifluoromethylphenyl valylglycine
    Patent number: 10449133
    Abstract: The present disclosure relates to cosmetic compositions including surprisingly high amounts of trifluoromethylphenyl valylglycine, which provides a variety of beneficial properties to skin. The cosmetic compositions include: (a) about 1 wt. % to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; (b) about 2 to about 30 wt. % of two or more solubilizing solvents selected from ethoxydiglycol, dimethyl isosorbide, triethyl citrate, isopropyl lauryl sarcosinate, and propylene glycol; and (c) optionally, water; wherein all weight percentages are based on the total weight of the cosmetic composition.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 22, 2019
    Assignee: L'OREAL
    Inventors: Jonathan James Faig, Zachary Maron
  • PSMA targeted nanobubbles for diagnostic and therapeutic applications
    Patent number: 10434194
    Abstract: A PSMA targeted nanobubble includes a membrane that defines at least one internal void, which includes at least one gas, and at least one PSMA ligand coupled or conjugated to the membrane. The membrane includes at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 8, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: James R. Basilion, Agata Exner, Xinning Wang, Christopher Hernandez
  • Substituted reverse pyrimidine Bmi-1 inhibitors
    Patent number: 10428050
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: October 1, 2019
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Therapeutic target for the treatment of cancers and related therapies and methods
    Patent number: 10420742
    Abstract: Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 24, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Mark Puder, Deepika Nehra, Brian Kalish
  • Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors
    Patent number: 10413547
    Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 17, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino